The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

PROVEN EFFICACY IN TREATING NAIL PSORIASIS1*

Sustained improvement in nail psoriasis up to 1 year1,a,b

Created with Highcharts 8.0.4Crossover to OTEZLA 30 mg BIDOTEZLA 30 mg BIDPlacebo-20020406080100Highcharts.com
0
Week 16
(n = 44)
(n = 42)
Week 32
(n = 45)
(n = 42)
Week 52
(n = 41)
(n = 39)
Mean Improvement From BL
in NAPSI score (%)
64%
60%
Sustained_improvement_in_scalp_psoriasis_up_to_1_year

aESTEEM 1 study. Data as observed; includes patients initially randomized to OTEZLA 30 mg BID or placebo at week 0 who were PASI-75 responders at week 32 and continued to receive OTEZLA through week 52.

bAt week 16, mean percent improvement in NAPSI score was significantly greater with OTEZLA 30 mg BID (22.5%, n = 339) vs placebo (-6.5%, n = 178). P < 0.0001; FAS, LOCF.

See the OTEZLA difference

Real patients, real pictures.

Actual patient with nail psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Baseline

Actual patient with nail psoriasis after 16 weeks of treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Week 16

Individual results may vary.

Actual patient with nail psoriasis after 32 weeks of treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Week 32

Individual results may vary.

*In patients with nail psoriasis at baseline (NAPSI score ≥1; 558/844, 66.1%).

Actual OTEZLA patient.

BID, twice daily; BL, baseline; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; FAS, full analysis set; LOCF, last observation carried forward; NAPSI, Nail Psoriasis Severity Index; PASI, Psoriasis Area and Severity Index.

OTEZLA IMPROVES NAIL PSORIASIS2,3

Sustained improvement in NAPSI score2,3,a

 

aLIBERATE study. Includes patients with NAPSI score ≥1 at baseline with a baseline value and a post-baseline value at the study week. Missing scores were imputed using the LOCF methodology. Mean NAPSI score at baseline was 4.14 (placebo) and 4.18 (OTEZLA).

bP = 0.4959, OTEZLA vs placebo.

LIBERATE, Evaluation in a Placebo-Controlled Study of Oral Apremilast and Etanercept in Plaque Psoriasis.

Nail psoriasis continues to improve for up to 2 years with OTEZLA2,3

References:

  1. Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018;32(3):397-402.
  2. Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol. 2017;31(3):507-517.
  3. Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018;32(3):397-402.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.